Neurana Pharmaceuticals, Inc.

Neuron23 Inc. aims to take two small molecule drug candidates for neurological diseases into the clinic during the next two years, with $100m from a series C venture capital round that the company an

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar

The frenzied flow of funds into biopharma venture capital has resulted in a lot of big bets, but recent small financings are encouraging as cash is harder to come by at the earliest stages of drug dis

“In the past there was a simple-minded notion that pain is pain is pain,” says Clifford Woolf, director of the F.M. Kirby Neurobiology Center at Children’s Hospital Boston and a professor of neurobiol